IPHASE DS8201a

Katerangan pondok:

DS-8201a, also known as trastuzumab deruxtecan (T-DXd), is an antibody-drug conjugate (ADC) designed for the treatment of HER2-positive cancers. It combines a HER2-targeting monoclonal antibody (similar to trastuzumab) with a potent topoisomerase I inhibitor (deruxtecan) as the cytotoxic payload. The drug delivers chemotherapy directly to cancer cells expressing HER2, improving efficacy while limiting damage to normal cells.

Rincian produk

Tag produk

  • katerangan produk DS-8201a, ogé katelah trastuzumab deruxtecan (T-DXd), nyaéta antibodi-drug conjugate (ADC) dirancang pikeun pengobatan HER2-kanker positip. Ieu ngagabungkeun hiji HER2-target antibodi monoklonal (sarupa trastuzumab) jeung topoisomerase I inhibitor kuat (deruxtecan) salaku payload sitotoksik. Ubar kasebut ngirimkeun kémoterapi langsung ka sél kanker anu nyatakeun HER2, ningkatkeun éfficacy bari ngawatesan karusakan sél normal.
    • Kategori:
      Cathepsin
    • Item NO.:
      015200.02
    • Ukuran Unit:
      200 uL, 2mg/mL
    • jaringan:
      N/A
    • Spésiés:
      N/A
    • Kaayaan neundeun sareng transportasi:
      Nyimpen dina -70°C. És garing dikirimkeun.

  • saméméhna:
  • Salajengna:
  • Pamilihan Basa